Related references
Note: Only part of the references are listed.Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2-microglobulin yields a more accurate GELTAMO-IPI
Carlos Montalban et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis
Mark J. Bishton et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma
Tarec Christoffer El-Galaly et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2-microglobulin
Thomas Melchardt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou et al.
BLOOD (2014)
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
David Cunningham et al.
LANCET (2013)
Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+ B-Cell Lymphoma in the Rituximab Era
Marita Ziepert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Laurie H. Sehn et al.
BLOOD (2007)
Share Paper
